1. Male or female >18 years of age at time of enrollment
2. The clinical diagnosis of stable plaque psoriasis
3. Two target plaques of similar severity
- ≥ 5 cm2 but ≤ 100 cm2 computed by multiplying the greatest diameter of the plaque
by the diameter of the plaque perpendicular to the greatest diameter
- Bilaterally located (right/left) plaques on the arms or distinct plaques located
on the trunk. Plaques located on the trunk must be separated by at least 10 cm
and will be designated by the Investigator as either left/right or front/back or
upper/lower
- Overall target plaque severity score (OTPSS) of 2-4 (mild to moderate) with no
more than a 1 point difference in the scores of the individual plaques
4. Normal or not clinically significant screening laboratory results
5. Willing and able to apply study drug as directed, comply with study instructions and
commit to all follow-up visits
6. Ability to understand, agree to and sign the study Informed Consent Form (ICF) prior
to initiation of any protocol related procedures
1. Any dermatological conditions that could interfere with clinical evaluations or any
disease state or physical condition which might expose the patient to an unacceptable
risk by study participation
2. Any underlying disease(s) or other dermatological conditions that require the use of
exclusionary topical or systemic therapy (see below).
3. Known sensitivity to any of the components of the study medication
4. Spontaneously improving or rapidly deteriorating psoriatic plaques or
pustular/exfoliative, guttate, erythrodermic or other non-plaque form of psoriasis
5. Concomitant use of topical or systemic therapies that might alter the course of
psoriasis
6. Females of child bearing potential. Females must be post-menopausal or surgically
sterile (oophorectomy).
7. Washout periods of:
- Topical drugs that might alter the course of psoriasis: 2 weeks
- Oral retinoids: 8 weeks
- Non-retinoid systemic drugs that might alter the course of psoriasis: 4 weeks
- PUVA: 4 weeks
- UVB therapy: 4 weeks
- Use of emollients/moisturizers on area(s) to be treated: 2 days to baseline visit
8. AIDS or AIDS related illness
9. Concurrent participation in another drug research study or within 30 days of
enrollment
10. Use of lithium or hydroxychloroquine containing products (i.e. Plaquenil)
11. Use of a beta-blocking medication (i.e. propranolol) if the dose has not been
stabilized for at least 3 months